Pharmacokinetic interactions between anticancer drugs and direct oral anticoagulants: clinical implications for safe anticoagulation
Bleeding, Thrombosis and Vascular Biology · Published 2026-04-16 · DOI 10.4081/btvb.2026.434
Free full text
Authors being retrieved — see the publisher record. https://doi.org/10.4081/btvb.2026.434
Abstract
Patients with cancer have an increased risk of thrombosis requiring anticoagulation. Direct oral anticoagulants have become the primary anticoagulant of choice in most patients with cancer. Patients with cancer also receive many concomitant medications, including anticancer therapies with potential risks of drug-drug interactions with anticoagulants that can lead to concerns of bleeding or recurrent thrombosis. The best management strategies remain unclear. In this article, we aim to review the available literature pertaining to pharmacokinetic interactions between anticancer therapies and direct oral anticoagulants and provide guidance based on the evidence.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2026
Related articles
- In this issue · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal
- Development of a shared decision-making tool for gene therapy in hemophilia A in Italy · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal
- Hormones, cancer, and thrombosis: sex-specific mechanisms at the interface of hemostasis and vascular biology · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal
- Platelet-derived thromboxane A2 induces cyclooxygenase-2 and epithelial-mesenchymal transition marker genes in U-87MG human glioblastoma cells · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal
- To P or not to P. That is the wrong question. · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal
- Availability of direct oral anticoagulants testing among Italian anticoagulation clinics: a rapid evolution of clinical practice · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal
- Thromboprophylaxis in primary brain cancer · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal
- Efficacy, safety and surgical management with concizumab prophylaxis in three young patients affected by severe hemophilia with inhibitors · Bleeding, Thrombosis and Vascular Biology · 2025 · Same journal
- Factor XI inhibitors in cancer-associated venous thromboembolism: what’s next? · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal
- Bleeding and thrombosis in patients receiving chimeric antigen receptor T-cell therapy · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal